AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,795,995 | -25.5% | 425,778 | -12.3% | 0.00% | 0.0% |
| Q2 2023 | $10,470,466 | -23.1% | 485,418 | +4.6% | 0.00% | -33.3% |
| Q1 2023 | $13,610,240 | -6.8% | 463,880 | +17.4% | 0.00% | 0.0% |
| Q4 2022 | $14,600,386 | +81.5% | 395,139 | +38.3% | 0.00% | +50.0% |
| Q3 2022 | $8,045,000 | +341.8% | 285,808 | +202.3% | 0.00% | – |
| Q2 2022 | $1,821,000 | +72.4% | 94,541 | +15.1% | 0.00% | – |
| Q1 2022 | $1,056,000 | – | 82,170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |